Gabrail Cancer and Research Center Receives FDA Clearance to Advance STAR-LLD and Elranatamab Study in Multiple Myeloma
The Gabrail Cancer and Research Center, a PhaseWell Research site, has announced an important regulatory milestone for an investigator-initiated clinical trial evaluating STAR-LLD in combination with elranatamab in patients with relapsed or refractory multiple myeloma. Nashat Gabrail, M.D., has received notification from the U.S. Food and Drug Administration (FDA) that the study may proceed under his Investigational New Drug (IND) application.
The planned clinical trial will investigate a novel approach to combining controlled low-dose delivery of lenalidomide with elranatamab, a B-cell maturation antigen (BCMA)-directed bispecific antibody. The study is designed to explore whether sustained immunomodulatory activity can enhance the effectiveness of T-cell engager therapy while potentially reducing some of the hematologic toxicity associated with conventional oral lenalidomide dosing.
Enrollment is anticipated to begin in the fourth quarter of 2026, subject to the completion of required approvals and other study requirements.
Exploring New Strategies for Relapsed or Refractory Multiple Myeloma
Multiple myeloma is a blood cancer characterized by the abnormal proliferation of plasma cells in the bone marrow. Although treatment options have expanded considerably, the disease remains difficult to cure, and many patients eventually experience relapse or become resistant to available therapies.
The development of T-cell engager therapies has introduced a new treatment strategy for patients with advanced disease. These therapies are designed to bring a patient’s T cells into close proximity with malignant cells, enabling the immune system to recognize and attack cancer cells.
BCMA-directed bispecific antibodies, including elranatamab, have become an increasingly important component of the therapeutic landscape for multiple myeloma. Their ability to engage immune cells directly with myeloma cells has created new opportunities for patients whose disease has progressed following previous treatments.
However, despite clinically meaningful responses in many patients, treatment resistance and disease progression remain important challenges. Researchers are continuing to investigate the biological mechanisms that may contribute to the loss of response over time and are evaluating combination strategies intended to improve the depth and durability of treatment responses.
Investigating T-Cell Fitness and Immune Modulation
One area of interest is the role of T-cell fitness and exhaustion in patients receiving T-cell engager therapies.
T-cell engagers depend on functional immune cells to produce their therapeutic effect. As treatment continues, changes in T-cell activity, phenotype, and function may contribute to declining treatment effectiveness. Emerging scientific evidence has suggested that T-cell exhaustion and reduced immune fitness could be among the factors associated with acquired resistance to these therapies.
This has prompted researchers to explore whether immune-modulating agents can be used alongside T-cell engagers to improve or sustain immune activity.
Immunomodulatory drugs, commonly referred to as IMiDs, have demonstrated the potential to influence immune responses and the tumor microenvironment. Lenalidomide is one such agent and has long played an important role in the treatment of multiple myeloma.
The STAR-LLD study is designed around the hypothesis that controlled delivery of lenalidomide could provide sustained immunomodulatory exposure while potentially reducing the high peak drug concentrations associated with conventional oral administration.
Rationale for Controlled Lenalidomide Delivery
Combining lenalidomide with T-cell engager therapy may provide a potential therapeutic advantage by influencing the immune environment in which the bispecific antibody operates. However, conventional lenalidomide administration can be associated with hematologic toxicities and an increased risk of infection.
These adverse effects can become particularly relevant when multiple therapies with overlapping safety considerations are administered together. Hematologic toxicity may lead physicians to reduce the dose of lenalidomide, interrupt treatment, or discontinue the IMiD altogether.
Such treatment modifications could potentially reduce the intended immunomodulatory effect of the combination.
The investigational STAR-LLD approach is intended to address this challenge through controlled low-dose delivery of lenalidomide. The strategy is designed to maintain sustained lenalidomide exposure at levels intended to support immunomodulatory activity while producing lower peak concentrations than conventional oral dosing.
The clinical study will examine whether this approach can provide a more favorable therapeutic profile when combined with elranatamab.
Importantly, the trial is investigational, and it remains to be determined whether controlled delivery of lenalidomide will reduce toxicity or improve treatment outcomes in patients with relapsed or refractory multiple myeloma.
Evaluating the Combination With Elranatamab
Elranatamab is a BCMA-directed bispecific antibody that works by engaging T cells and directing them toward BCMA-expressing myeloma cells. This mechanism allows the patient’s own immune system to participate directly in the elimination of malignant plasma cells.
T-cell engager therapies offer several practical advantages compared with certain other cellular immunotherapies. For example, CAR-T cell therapy requires the collection and modification of a patient’s cells, specialized manufacturing processes, and treatment at appropriately equipped centers.
Bispecific antibody therapies can potentially be delivered through established oncology treatment infrastructure under appropriate clinical protocols. This creates opportunities for their use beyond highly specialized academic centers and may increase access for patients who receive cancer treatment in community oncology settings.
Nevertheless, treatment-associated toxicities and the potential for resistance continue to require attention. The STAR-LLD study seeks to explore whether modifying the immunomodulatory component of treatment could improve the overall therapeutic experience.
Community Oncology as a Key Setting for Research
The clinical trial will be conducted at the Gabrail Cancer and Research Center, highlighting the increasingly important role of community oncology practices in clinical research.
Nashat Gabrail, M.D., who is leading the investigator-initiated study, emphasized the challenge of combining immunomodulatory agents with T-cell engager therapies.
According to Dr. Gabrail, additive hematologic toxicity can result in IMiD dose reductions and potentially undermine the intended therapeutic strategy. He believes STAR-LLD’s controlled delivery profile provides an opportunity to investigate whether sustained exposure can preserve or potentially improve efficacy while reducing the burden of hematologic toxicity.
He also expressed interest in whether the approach could potentially extend the duration of response to bispecific antibody therapy.
The study therefore represents an effort to address a clinically relevant challenge through a modified drug-delivery strategy rather than simply increasing or maintaining conventional dosing.
PhaseWell Research Supports Investigator-Initiated Innovation
PhaseWell Research is supporting the clinical research program as the Gabrail Cancer and Research Center’s research site.
Carsten Bick, Chief Executive Officer of PhaseWell Research, emphasized the organization’s goal of making innovative research available through community-based investigators.
According to Bick, one of the key roles of PhaseWell Research is to help investigators conduct advanced clinical research in community settings. This approach can allow patients who may not routinely travel to major academic medical centers to participate in clinical studies involving emerging treatment strategies.
The organization views the STAR-LLD study as an example of investigator-led research being conducted within a community oncology environment. Such studies can generate evidence from patient populations treated in everyday clinical settings and potentially provide information that complements research performed at large academic institutions.
Generating Real-World Clinical Evidence
Carrie Smith, RN, Chief Operations Officer of the Research Division, highlighted the importance of conducting the study at the Gabrail Cancer and Research Center.
According to Smith, T-cell engager therapies are increasingly being incorporated into community oncology practice, making it important to understand how new treatment combinations perform in settings where many patients receive routine cancer care.
Community-based clinical research can potentially provide investigators with access to patient populations that reflect broader clinical practice. This can be valuable when evaluating safety, tolerability, treatment administration, and other practical considerations associated with emerging therapies.
For multiple myeloma, where patients may undergo numerous lines of therapy over the course of their disease, generating evidence from community settings could help inform how innovative combinations are incorporated into treatment pathways.
Potential to Address Treatment-Related Challenges
The STAR-LLD clinical program is centered on two interconnected challenges: maintaining effective immune modulation and managing treatment-related toxicity.
The scientific rationale behind the study is based on the possibility that sustained, controlled exposure to lenalidomide could provide immunomodulatory activity while avoiding some of the higher peak concentrations associated with standard oral dosing.
If successful, such an approach could potentially allow researchers to explore whether lenalidomide can complement T-cell engager therapy without creating an unacceptable increase in hematologic toxicity.
The study will also contribute to the broader scientific understanding of how IMiDs and T-cell engagers can be combined. Previous clinical and scientific research has provided evidence supporting the potential of immunomodulatory therapies to influence the activity of T-cell-based cancer treatments.
However, determining the optimal dosing strategy, treatment schedule, and safety profile remains an important area of investigation.
FDA authorization to proceed under the investigator’s IND represents an important step toward initiating the STAR-LLD clinical trial. With enrollment expected to begin in Q4 2026, the study team will now focus on completing the necessary preparations before participants can enter the trial.
The upcoming research will provide an opportunity to evaluate controlled low-dose lenalidomide delivery in combination with elranatamab in people living with relapsed or refractory multiple myeloma.
The study’s findings could help determine whether sustained immunomodulatory exposure can influence the effectiveness or tolerability of BCMA-directed bispecific antibody therapy. The research may also provide insights into the feasibility of delivering innovative treatment combinations in community oncology settings.
At present, STAR-LLD remains an investigational approach, and no conclusions can yet be drawn regarding its safety or effectiveness. Clinical trial data will be required to establish whether the proposed strategy delivers meaningful benefits for patients.
Nevertheless, the FDA’s decision allowing the investigator-initiated study to proceed marks a significant development for the Gabrail Cancer and Research Center, PhaseWell Research, and the broader effort to improve treatment strategies for relapsed or refractory multiple myeloma.
By combining a BCMA-directed T-cell engager with a controlled-delivery immunomodulatory approach, the research team hopes to investigate whether treatment efficacy and tolerability can be optimized simultaneously. The study also reflects the growing role of community oncology research in bringing innovative therapeutic concepts closer to the patients who may ultimately benefit from them.
As enrollment approaches, the STAR-LLD program will provide an opportunity to generate clinical evidence around a novel strategy for combining lenalidomide with elranatamab and potentially contribute to the ongoing evolution of treatment options for patients with difficult-to-treat multiple myeloma.
About Gabrail Cancer Center
The Gabrail Cancer and Research Center, a PhaseWell Research site, is based in Canton, Ohio, and provides comprehensive cancer care and conducts clinical research across a broad range of hematologic and solid tumor malignancies. Led by Nashat Gabrail, M.D., the Center is committed to bringing novel investigational therapies to patients in a community oncology setting.
To learn more, visit www.gabrailcancercenter.com. Media inquiries may be directed to Carrie Smith at csmith@gabrailcancercenter.com.
About PhaseWell Research
PhaseWell Research is a multisite clinical research organization operating wholly owned investigator-led sites across the United States. The company partners with sponsors and CROs to support Phase I–IV clinical trials across complex, high-demand therapeutic areas, including oncology, central nervous system, and cardiometabolic conditions. Rooted in the communities it serves, PhaseWell expands access to advanced clinical research for patients who may otherwise have limited opportunities to participate. The network has completed more than 2,700 clinical trials and contributed to the approval of more than 200 therapies. For more information, visit www.phasewell.com.
STAR-LLD and its use in combination with elranatamab are investigational. FDA clearance to proceed reflects the absence of a clinical hold after the required safety review and does not constitute FDA approval or an assessment of the combination’s safety or efficacy. The safety and effectiveness of the combination have not been established, and the combination has not been approved by FDA.
This press release contains forward-looking statements, including statements regarding the design, timing, and anticipated enrollment of the investigator-initiated study, the potential benefits of combining STAR-LLD with elranatamab, and the study’s ability to affect response durability or hematologic toxicity. Words such as “anticipated,” “may,” “potential,” “designed to,” “intended,” “opportunity,” and similar expressions are intended to identify forward-looing statements.
These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including risks related to clinical trial enrollment, conduct, and results; regulatory review; and the fact that the combination of STAR-LLD and elranatamab is investigational, has not been approved by the FDA, and its safety and effectiveness have not been established. Actual results may differ materially from those expressed or implied by these statements. Gabrail Cancer Center and PhaseWell Research undertakes no obligation to update these statements except as required by law.